Skip to content

A Relevance Study Between the Result of Clinical Drug Intervention and Next-generation Sequencing Technology Focused on Refractory Helicobacter Pylori Infection

A Relevance Study Between the Result of Clinical Drug Intervention and Next-generation Sequencing Technology Focused on Refractory Helicobacter Pylori Infection

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02806674
Enrollment
1845
Registered
2016-06-21
Start date
2016-07-31
Completion date
2019-12-31
Last updated
2017-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastritis

Keywords

Helicobacter pylori, Antibiotic resistance, Sequencing

Brief summary

Approximately 50% of people in the world are infected with H. pylori, and its eradication rate fail to exceed 80% and even fails into an unacceptable range.Various risk factors for infection include lower socioeconomic status, younger age, and geographic location.In the present study, investigators aimed to perform a prevalence survey about risk factors for H. pylori infection.To obtain the higher eradication of H. pylori and find out the relevance between the diverse infection and clinical drug focused on refractory H. pylori infection.

Interventions

DEVICEThe eradication times of the patients

The patients who have failed more than 2 eradication courses with standardized treatment were the refractory infection of H. pylori group,and patients who succeeded at the first standardized treatment were the successful treatment group

DEVICEThe result of 13C-urea breath test after treatment

The intervention focused on the results from the result of 13C-urea breath test after treatment.The two groups were treatment based on the antibiotic susceptibility testing. Eight weeks after treatment,a 13C-urea breath test was performed on patients.The successful treatment group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients after the second standardized treatment.

Sponsors

People Hospital of Luohu,Shenzhen
CollaboratorUNKNOWN
Shenzhen Second People's Hospital
CollaboratorOTHER
Longhua Branch of Shenzhen People Hospital
CollaboratorUNKNOWN
The People Hospital of Baoan Shenzhen
CollaboratorOTHER
Zhiyuan Medical Inspection Institute
CollaboratorOTHER
The University of Hong Kong-Shenzhen Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Age 18\ 70 years old, male or female, untreated patients. 2. Symptoms of abdominal pain, bloating, acid reflux,belching,nausea,vomiting,heartburn, chest pain, vomiting, melena, etc. 3. Unused antibiotics, bismuth, H2 receptor antagonists or PPI by nearly 4 weeks 4. 13C-labelled urea breath test positive. 5. Agreed to Helicobacter pylori culture and sensitivity testing taken by endoscopy gastric biopsy specimens,and the result of culture was positive. 6. Agreed to Helicobacter pylori eradication therapy and cooperate with the eradication efficacy follow-up survey.

Exclusion criteria

1. Severe heart, liver, kidney dysfunction. 2. Pregnant or lactating women. 3. Complications of bleeding, perforation, pyloric obstruction, cancer. 4. Esophageal,gastrointestinal surgery history. 5. Patients can not properly express their complaints,such as psychosis, severe neurosis. 6. Taking NSIAD or alcohol abusers. 7. Allergic to penicillin or either drugs of the 6 antibiotic tested by susceptibility testing.

Design outcomes

Primary

MeasureTime frameDescription
The eradication rate of H. pylori reach to 95%1.5 yearThe eradication rate of untreated cases reach to 98%.The eradication rate of refractory cases reach to 90%.
Obtain the first resistant pattern to antibiotics in shenzhen area1.5 yearThe results of antibiotic susceptibility testing were analyzed in this study.More than 1800 patients were participated,these patients were representative in five hospitals of shenzhen area.
The proportion of mix infection of H pylori in a total of 40 patients in two groups2.5 yearAnalyzed the next-generation sequencing data,obtain the proportion of mixed infection with different H. pylori strain in refractory cases.

Secondary

MeasureTime frameDescription
The incidence of adverse effects in the eradicate treatment2.5 yearA telephone interview was conducted at 4 weeks after treatment.And the 1845 patients was investigated using questionnaires of symptom checklist.A statistics table will be got.
The difference between microbial genes of different patients3 yearBy 2 or 3 metabolic pathways with significant differences, selected 40-50 different genes.
The relevance between mixed infection, microflora structure and risk factors3 yearAnalyzed the next-generation sequencing data,obtain the results of mixed infection and microflora structure in a total of 40 patients in two groups.And the patients was investigated using questionnaires of risk checklist.The collected data were subsequently analyzed using SPSS. For checking the relationship between mixed infection, microflora structure and risk factors.

Countries

China

Contacts

Primary ContactTao Lyu, Doctor
lvt@hku-szh.org

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026